The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 895 studies for Leukemia, Myelogenous, Chronic, BCR-ABL Positive across more than 10 countries. 107 are recruiting or about to start. 516 of them are mainly about Leukemia, Myelogenous, Chronic, BCR-ABL Positive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its 3 narrower conditions too, such as Leukemia, Myeloid, Chronic-Phase: 1,317 studies, 127 open.
ClinicalTrials.gov finds 1,304 studies for Leukemia, Myelogenous, Chronic, BCR-ABL Positive.How that becomes 895 hereChecked on ClinicalTrials.gov . The studies here are updated every night.
This page counts the studies the registry files under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, and those it files under no condition that list Leukemia, Myelogenous, Chronic, BCR-ABL Positivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count
−1List Leukemia, Myelogenous, Chronic, BCR-ABL Positive as a condition, but the registry did not file them under itMost often written as “Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative” (1) and “Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive” (1). The registry filed them under other conditions only, most often Leukemia, Biphenotypic, Acute (1) and Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (1).
−6Match it another way3 name it in the title and 3 by a synonym or other text the search reads.
879Counted here and found by its search
+16Counted here, but its search does not find themThe registry filed them under no condition; they name Leukemia, Myelogenous, Chronic, BCR-ABL Positive in their own words, such as “Chronic Myeloid Leukemia in Chronic Phase” (4), “Chronic Myeloid Leukemia in Remission” (2), and “Chronic Phase Ph+ Chronic Myeloid Leukemia” (1), which its search for Leukemia, Myelogenous, Chronic, BCR-ABL Positive does not match.
Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 6 with this as their studies’ main aim; 4 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Hansoh Pharmaceutical Group and Novartis here →
Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
vs bosutinibvs Dasatinibvs imatinib · own drug+1 more
The 4 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (1)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
3 Sept 2027 est.asciminib· Novartis · Phase 2main aimNCT04925479 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia — primary endpoint: Primary Pharmacokinetic (PK) parameter: AUClast · 46 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
44studies finish main data collection within a year2 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 77 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 47 (61%) set no upper age limit and 19 (25%) stop at 75 or younger. 20 (26%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 7 (9%) take healthy volunteers.
Across all 895 studies, recruiting or not: 35% stop at 75 or younger and 20% at 65; 29% take children; <1% are for women only and 1% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies take
Of 125 phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 73 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
58 mo41–95 · 56 studies
—
—
Phase 1/2
69 mo56–94 · 26 studies
—
—
Phase 2
73 mo42–121 · 125 studies
44 mo33–69 · 25 studies
75 mo50–130 · 100 studies
Phase 3
38 mo30–79 · 24 studies
—
—
Interventional, no phase
41 mo22–123 · 25 studies
—
—
Observational
53 mo39–103 · 67 studies
—
58 mo46–142 · 45 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 19, 2026.